Trial reportDrug design, development and therapy2025
Comparison of Remimazolam and Dexmedetomidine on Postoperative Delirium and Emergence Agitation in Elderly Patients Undergoing Thoracoscopic Surgery: A Randomized, Double-Blind, Non-Inferiority Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of remimazolam on postoperative neurocognitive disorder in elderly surgical patients: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Effect of remimazolam on postoperative delirium in elderly patients undergoing laparoscopic radical resection for colorectal cancer: a randomized controlled trial.BMC gastroenterology · 2026Trial
- Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Postoperative delirium (POD) and emergence agitation (EA) are common complications in older patients undergoing video-assisted thoracoscopic surgery (VATS), significantly impacting recovery. This study was designed to examine whether remimazolam is noninferior to dexmedetomidine for preventing POD and EA in elderly patients following VATS. Patients and Methods: A total of 176 elderly patients scheduled for VATS due to lung cancer were randomly assigned to receive either dexmedetomidine (Group D, n = 88) or remimazolam (Group R, n = 88). Group D received dexmedetomidine at 0.5 μg/kg/h starting 3 minutes before anesthesia induction until surgery completion. Group R received remimazolam at 0.5 mg/kg/h over the same period. The primary outcomes were the incidence of EA and POD within 5 days after surgery. Secondary outcomes included Quality of Recovery-15 (QoR-15) score, Athens Insomnia Scale (AIS), and numeric rating scale (NRS) for pain. Correlations among hypotension, EA, and POD were also analyzed. Results: The incidence of POD and EA in Group R was non-inferior to that in Group D (non-inferiority Conclusion: Remimazolam was non-inferior to dexmedetomidine in preventing POD and EA in elderly patients undergoing VATS while providing improved hemodynamic stability and reducing the need for intraoperative opioids and vasopressors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.